EGR1介导的代谢重编程至氧化磷酸化促进B细胞淋巴瘤对伊布替尼耐药
研究显示,在伊布替尼耐药的活化B细胞样亚型弥漫大B细胞淋巴瘤(DLBCL)和套细胞淋巴瘤(MCL)细胞中EGR1表达升高,且伊布替尼处理可进一步上调EGR1。TCF4与EGR1自身调控诱导EGR1过表达,通过转录激活PDP1介导代谢重编程至氧化磷酸化(OXPHOS),增加ATP产生以支持耐药细胞增殖存活。二甲双胍或IM156靶向OXPHOS可抑制耐药细胞生长,提示潜在治疗策略。
要点
- EGR1在伊布替尼耐药的活化B细胞样DLBCL和MCL细胞中表达升高。
- EGR1通过转录激活PDP1介导代谢重编程至OXPHOS,增加ATP产生。
- 二甲双胍或IM156靶向OXPHOS可抑制伊布替尼耐药淋巴瘤细胞生长。
核心结论
- 靶向EGR1介导的代谢重编程至OXPHOS(二甲双胍或IM156)为克服复发/难治性DLBCL或MCL的伊布替尼耐药提供了潜在治疗策略。
研究设计与样本
- 研究采用伊布替尼耐药的活化B细胞样亚型DLBCL和MCL细胞,进行遗传学和药理学分析,并在患者来源异种移植小鼠模型中验证。
主要发现
- EGR1在伊布替尼耐药的活化B细胞样DLBCL和MCL细胞中表达升高,且伊布替尼处理可进一步上调EGR1。
- 过表达EGR1介导伊布替尼耐药;TCF4和EGR1自身调控诱导EGR1过表达。
- EGR1通过转录激活PDP1介导代谢重编程至OXPHOS,PDP1使大型丙酮酸脱氢酶复合体E1组分去磷酸化并激活。
- EGR1介导的PDP1激活增加细胞内ATP产生,增强伊布替尼耐药淋巴瘤细胞的增殖和存活。
- 二甲双胍或IM156在体外和患者来源异种移植小鼠模型中抑制伊布替尼耐药淋巴瘤细胞生长。
临床怎么用
- 作者认为,使用二甲双胍或IM156靶向EGR1介导的代谢重编程至OXPHOS,是克服复发/难治性DLBCL或MCL伊布替尼耐药的潜在治疗策略。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The use of Bruton tyrosine kinase inhibitors, such as ibrutinib, to block B-cell receptor signaling has achieved a remarkable clinical response in several B-cell malignancies, including mantle cell lymphoma (MCL) and diffuse large B-cell lymphoma (DLBCL). Acquired drug resistance, however, is significant and affects the long-term survival of these patients. Here, we demonstrate that the transcription factor early growth response gene 1 (EGR1) is involved in ibrutinib resistance. We found that EGR1 expression is elevated in ibrutinib-resistant activated B-cell-like subtype DLBCL and MCL cells and can be further upregulated upon ibrutinib treatment. Genetic and pharmacological analyses revealed that overexpressed EGR1 mediates ibrutinib resistance. Mechanistically, TCF4 and EGR1 self-regulation induce EGR1 overexpression that mediates metabolic reprogramming to oxidative phosphorylation (OXPHOS) through the transcriptional activation of PDP1, a phosphatase that dephosphorylates and activates the E1 component of the large pyruvate dehydrogenase complex. Therefore, EGR1-mediated PDP1 activation increases intracellular adenosine triphosphate production, leading to sufficient energy to enhance the proliferation and survival of ibrutinib-resistant lymphoma cells. Finally, we demonstrate that targeting OXPHOS with metformin or IM156, a newly developed OXPHOS inhibitor, inhibits the growth of ibrutinib-resistant lymphoma cells both in vitro and in a patient-derived xenograft mouse model. These findings suggest that targeting EGR1-mediated metabolic reprogramming to OXPHOS with metformin or IM156 provides a potential therapeutic strategy to overcome ibrutinib resistance in relapsed/refractory DLBCL or MCL.
引用
- Liu Y, Kimpara S, Hoang NM, et al. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023. PMID: 37738652. doi:10.1182/blood.2023020142
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。